315 related articles for article (PubMed ID: 17937915)
1. Partial agonists activate PPARgamma using a helix 12 independent mechanism.
Bruning JB; Chalmers MJ; Prasad S; Busby SA; Kamenecka TM; He Y; Nettles KW; Griffin PR
Structure; 2007 Oct; 15(10):1258-71. PubMed ID: 17937915
[TBL] [Abstract][Full Text] [Related]
2. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.
Waku T; Shiraki T; Oyama T; Fujimoto Y; Maebara K; Kamiya N; Jingami H; Morikawa K
J Mol Biol; 2009 Jan; 385(1):188-99. PubMed ID: 18977231
[TBL] [Abstract][Full Text] [Related]
3. Hydrogen/deuterium-exchange (H/D-Ex) of PPARgamma LBD in the presence of various modulators.
Hamuro Y; Coales SJ; Morrow JA; Molnar KS; Tuske SJ; Southern MR; Griffin PR
Protein Sci; 2006 Aug; 15(8):1883-92. PubMed ID: 16823031
[TBL] [Abstract][Full Text] [Related]
4. Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping.
Sheu SH; Kaya T; Waxman DJ; Vajda S
Biochemistry; 2005 Feb; 44(4):1193-209. PubMed ID: 15667213
[TBL] [Abstract][Full Text] [Related]
5. Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities.
Lu IL; Huang CF; Peng YH; Lin YT; Hsieh HP; Chen CT; Lien TW; Lee HJ; Mahindroo N; Prakash E; Yueh A; Chen HY; Goparaju CM; Chen X; Liao CC; Chao YS; Hsu JT; Wu SY
J Med Chem; 2006 May; 49(9):2703-12. PubMed ID: 16640330
[TBL] [Abstract][Full Text] [Related]
6. Protein polarization is critical to stabilizing AF-2 and helix-2' domains in ligand binding to PPAR-gamma.
Ji CG; Zhang JZ
J Am Chem Soc; 2008 Dec; 130(50):17129-33. PubMed ID: 19007119
[TBL] [Abstract][Full Text] [Related]
7. Atomic structure of mutant PPARgamma LBD complexed with 15d-PGJ2: novel modulation mechanism of PPARgamma/RXRalpha function by covalently bound ligands.
Waku T; Shiraki T; Oyama T; Morikawa K
FEBS Lett; 2009 Jan; 583(2):320-4. PubMed ID: 19101554
[TBL] [Abstract][Full Text] [Related]
8. Probing protein ligand interactions by automated hydrogen/deuterium exchange mass spectrometry.
Chalmers MJ; Busby SA; Pascal BD; He Y; Hendrickson CL; Marshall AG; Griffin PR
Anal Chem; 2006 Feb; 78(4):1005-14. PubMed ID: 16478090
[TBL] [Abstract][Full Text] [Related]
9. The dipeptide H-Trp-Glu-OH shows highly antagonistic activity against PPARgamma: bioassay with molecular modeling simulation.
Ye F; Zhang ZS; Luo HB; Shen JH; Chen KX; Shen X; Jiang HL
Chembiochem; 2006 Jan; 7(1):74-82. PubMed ID: 16317783
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.
Montanari R; Saccoccia F; Scotti E; Crestani M; Godio C; Gilardi F; Loiodice F; Fracchiolla G; Laghezza A; Tortorella P; Lavecchia A; Novellino E; Mazza F; Aschi M; Pochetti G
J Med Chem; 2008 Dec; 51(24):7768-76. PubMed ID: 19053776
[TBL] [Abstract][Full Text] [Related]
11. The differential interactions of peroxisome proliferator-activated receptor gamma ligands with Tyr473 is a physical basis for their unique biological activities.
Einstein M; Akiyama TE; Castriota GA; Wang CF; McKeever B; Mosley RT; Becker JW; Moller DE; Meinke PT; Wood HB; Berger JP
Mol Pharmacol; 2008 Jan; 73(1):62-74. PubMed ID: 17940191
[TBL] [Abstract][Full Text] [Related]
12. Ligand-induced stabilization and activation of peroxisome proliferator-activated receptor gamma.
Gani OA; Sylte I
Chem Biol Drug Des; 2008 Jul; 72(1):50-7. PubMed ID: 18554251
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of docosahexaenoic acid derivatives designed as novel PPARgamma agonists and antidiabetic agents.
Itoh T; Murota I; Yoshikai K; Yamada S; Yamamoto K
Bioorg Med Chem; 2006 Jan; 14(1):98-108. PubMed ID: 16198578
[TBL] [Abstract][Full Text] [Related]
14. Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies.
Mahindroo N; Wang CC; Liao CC; Huang CF; Lu IL; Lien TW; Peng YH; Huang WJ; Lin YT; Hsu MC; Lin CH; Tsai CH; Hsu JT; Chen X; Lyu PC; Chao YS; Wu SY; Hsieh HP
J Med Chem; 2006 Feb; 49(3):1212-6. PubMed ID: 16451087
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for differential activities of enantiomeric PPARĪ³ agonists: Binding of S35 to the alternate site.
Jang JY; Koh M; Bae H; An DR; Im HN; Kim HS; Yoon JY; Yoon HJ; Han BW; Park SB; Suh SW
Biochim Biophys Acta Proteins Proteom; 2017 Jun; 1865(6):674-681. PubMed ID: 28342850
[TBL] [Abstract][Full Text] [Related]
16. Manipulation of reciprocal salt bridges at the heterodimerization interface alters the dimerization properties of mouse RXRalpha and PPARgamma1.
Chan LS; Wells RA
Biochem Biophys Res Commun; 2007 Jul; 358(4):1080-5. PubMed ID: 17521607
[TBL] [Abstract][Full Text] [Related]
17. Computational screening of phthalate monoesters for binding to PPARgamma.
Kaya T; Mohr SC; Waxman DJ; Vajda S
Chem Res Toxicol; 2006 Aug; 19(8):999-1009. PubMed ID: 16918238
[TBL] [Abstract][Full Text] [Related]
18. Continuous nucleocytoplasmic shuttling underlies transcriptional activation of PPARgamma by FABP4.
Ayers SD; Nedrow KL; Gillilan RE; Noy N
Biochemistry; 2007 Jun; 46(23):6744-52. PubMed ID: 17516629
[TBL] [Abstract][Full Text] [Related]
19. Insights into PPARgamma from structures with endogenous and covalently bound ligands.
Nettles KW
Nat Struct Mol Biol; 2008 Sep; 15(9):893-5. PubMed ID: 18769464
[No Abstract] [Full Text] [Related]
20. Deoxyelephantopin inhibits cancer cell proliferation and functions as a selective partial agonist against PPARgamma.
Zou G; Gao Z; Wang J; Zhang Y; Ding H; Huang J; Chen L; Guo Y; Jiang H; Shen X
Biochem Pharmacol; 2008 Mar; 75(6):1381-92. PubMed ID: 18164690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
